Clinical trials: Major Depressive Disorder, completed
Depression, Excessive Daytime Sleepiness
Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder
This concurrent, two-part study will: I) Using overnight sleep recordings, evaluate the short- and long-term sleep-promoting effects of the antidepressant mirtazapine (Remeron) in patients who have been prescribed this medication…
- Trial name
- NCT00385437
- Testing
- Driving Simulator Testing, Mirtazapine Treatment
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- University Health Network, Toronto
Depressive Disorder, Major
The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD
To determine if the NMDA antagonist, CP-101,606, is effective for depression
- Trial name
- NCT00163059
- Testing
- NMDA Antagonist, CP-101,606 (traxoprodil)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Pfizer
Major Depression
Testosterone and Major Depression
Context - As men age, testosterone levels decline leading to symptoms that overlap with the symptoms of major depression. Little is known about the potential role of testosterone in the treatment of major depression.Objective …
- Trial name
- NCT00286546
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Major Depressive Disorder
A Study of the Cost Effectiveness of Generalist Care Managers for Depression Treatment in Medicaid Recipients
This project will enable the investigators to conduct a randomized clinical trial to demonstrate the value of generalist care managers in the treatment of depression in Medicaid patients seen in primary health care practices.
- Trial name
- NCT00373477
- Testing
- Generalist Care Manager vs Usual Care
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- University of North Carolina
Major Depression
Antidepressant Prophylaxis for Interferon-Induced Depression: Efficacy of Paroxetine
Objectives: 1. To determine whether paroxetine can prevent major depression in patients with hepatitis C (HCV) who are receiving pegylated-interferon (Peg-IFN). 2.
- Trial name
- NCT00357045
- Testing
- Paroxetine
- Sponsor
- Portland VA Medical Center
Depressive Disorder, Major
Duloxetine in the Treatment of Melancholic Depression
The purpose of this study is to determine the optimal treatment strategy for MDD patients with melancholic features who do not respond to a standard daily dose.
- Trial name
- NCT00191685
- Testing
- duloxetine
- Where
- 23 sites in Australia, Canada
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Switching to Duloxetine From Other Antidepressants
A multicentre, randomised, open label study of out-patients with major depression who have failed to respond adequately to antidepressant treatment for their current episode of depression.
- Trial name
- NCT00191932
- Testing
- Duloxetine
- Where
- 14 sites in France, Ireland and 2 more
- Volunteers
- 360 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression
The purposes of this study are to determine: Whether olanzapine plus fluoxetine in combination will help patients with treatment-resistant major depression.
- Trial name
- NCT00035321
- Testing
- Olanzapine, Fluoxetine
- Where
- 33 sites in United States, Canada
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
Depressive Disorder
Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder
The purpose of this study is to determine if duloxetine is effective when compared to placebo in preventing recurrence of major depressive disorder in patients who have responded to open-label duloxetine treatment.
- Trial name
- NCT00036309
- Testing
- Duloxetine Hydrochloride
- Where
- United States
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major Depression
The purposes of this study are to determine: The safety of duloxetine and any side effects that might be associated with it. Whether duloxetine can help patients with major depression.
- Trial name
- NCT00042562
- Testing
- duloxetine
- Where
- 23 sites in United States
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression
The Purposes of this Study are to determine: The safety of duloxetine and any side effects that might be associated with it. Whether duloxetine can help patients with major depression.
- Trial name
- NCT00042575
- Testing
- Duloxetine
- Where
- 9 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Schizophrenia, Major Depression
Effect of Specific Anti-Toxoplasmatic Add-on Medication in Toxoplasma Gondii Seropositive Individuals With Schizophrenia or Major Depression
We investigate whether the add-on specific antitoxoplasmatic medication has positive effects in individuals with schizophrenia or major depression seropositive for Toxoplasma gondii (TG) infection.
- Trial name
- NCT00300404
- Testing
- daraprim, pyrimethamine, folinic acid
- Volunteers
- 40 people
- Sponsor
- Zentrum für Integrative Psychiatrie
Major Depressive Disorder
Continuation Electroconvulsive Therapy Vs Medication to Prevent Relapses in Patients With Major Depressive Disorder
The purpose of this study is to compare the safety and effectiveness of two treatments to prevent relapses in seriously ill patients with major depressive disorder (MDD) who have responded to electroconvulsive therapy (ECT).
- Trial name
- NCT00000375
- Testing
- Nortriptyline-lithium (NOR-Li), Bilateral electroconvulsive therapy (ECT), Continuation therapy
- Where
- United States
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depression
Depression: The Search for Treatment-Relevant Phenotypes-Pilot Study
We are doing this pilot study to learn more about four aspects of treating depression: 1. The features of a depressed person's mood and anxiety and how these features affect a person's capacity to get better and stay better. 2.
- Trial name
- NCT00222820
- Testing
- escitalopram, Interpersonal Psychotherapy
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Pittsburgh
Major Depressive Disorder
Metyrapone as Additive Treatment in Major Depression
The purpose of this study is to test whether metyrapone is an effective and safe augmenting agent in the treatment of major depression.
- Trial name
- NCT00125554
- Testing
- Metyrapone
- Where
- Germany
- Volunteers
- 63 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf